Search for: "In Re: Pfizer Securities Litigation" Results 1 - 20 of 105
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Mar 2024, 12:30 pm by John Ross
 Seventh Circuit: Sovereign immunity means never having to say you're sorry. [read post]
8 Jun 2023, 7:43 am by Ashwin Varma
Horizon’s strategy shifted over time, however, with the firm seeking to purchase undervalued therapeutics from bankrupt pharmaceutical companies and then re-launch them. [read post]
13 Mar 2022, 9:41 am by Dave Maass
Worst of all, they also refused to divulge the purchase price–even though we're talking about public money. [read post]
2 Mar 2022, 2:33 pm
    That’s why the NATO Alliance was created to secure peace and stability in Europe after World War 2. [read post]
18 Feb 2022, 7:33 am by Jonathan M. Barnett
The FTC’s case against Illumina’s re-acquisition of GRAIL relies on theoretical predictions of consumer harm in a market that is not yet operational. [read post]
10 Jan 2022, 4:01 pm by INFORRM
Hacked Off has re-published lessons from the phone hacking scandal: 10 years on, first published on Campaign.org. [read post]
25 Sep 2021, 2:36 pm by Eugene Volokh
Minn. 2021) (noting how an individual's prior infection with COVID-19 "provide[d] him with some natural immunity and lessen[[ed] his risk of re-infection"). [read post]
9 Aug 2021, 2:02 am by Deb Givens
  Are companies securing unwarranted monopoly power by raising barriers to litigating the validity of their patents? [read post]
1 Sep 2020, 4:19 pm by Robert McKennon
Attorneys say they not only drive up the cost of litigation and discourage people from suing for benefits they’re owed, they violate the law Congress passed to protect the millions of people who participate in employee benefit plans, which include retirement, pension, 401(k), health-care, disability and life insurance plans. [read post]
9 Mar 2020, 1:21 pm by Unknown
Would help litigation, clarity. $3 million to litigate a patent, which is a big expense. [read post]
12 Nov 2017, 11:00 pm by Kevin LaCroix
Building on its recent decision in In re Petrobras Securities Litigation,[9] the Second Circuit held that a plaintiff need not always offer direct event study evidence of a cause-and-effect relationship between new information and stock price movements before satisfying its burden to prove market efficiency at the class certification stage. [read post]
25 May 2016, 3:46 pm by Lyle Roberts
” In In re Pfizer Inc. [read post]
14 Apr 2016, 4:59 pm by Kevin LaCroix
  That theory has been a primary enabler of class action securities litigation under Section 10(b) of the Securities Exchange Act of 1934. [read post]